Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2025 to Question 35541 and and the Answer of 12 May to Question 50770 on Hormone Replacement Therapy, (a) what progress has been made and (b) what further steps are being taken to ensure a continued supply of HRT implants for patients.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is continuing to work closely with the Medicines and Healthcare products Regulatory Agency (MHRA) to ensure safe access to oestrogen and testosterone hormone replacement therapy (HRT) implants, which are not licensed in the United Kingdom.

The MHRA has been working closely with the current importers of the product and is also looking to encourage other applications for a licensed medicinal product. The MHRA is currently assured that there are over 13 months of product in the UK based on currently available stocks and usage rates.

As oestrogen and testosterone HRT implants are not licensed in the UK, we are encouraging applications to supply products through the licensed medicines route.

The Department is working closely with the MHRA to ensure safe access to these products. The Department have also reached out to specialist importers, who can source unlicensed medicines, to find alternative sources of both HRT implants for UK patients. The Department will continue to work closely with the MHRA and the National Health Service to ensure that suitable alternatives are available for patients.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what steps she is taking to help ensure that parents receive adequate information on (a) the use of (i) parental controls and (ii) virtual private networks and (b) other steps to keep children safe online.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

DSIT has funded media literacy projects, including Parent Zone’s ‘Everyday Digital’, to help parents understand online safety. On 12 September 2025, DSIT published research exploring what support parents need to keep children safe online. Ofcom has also released a guide for parents on how new Online Safety Act measures will protect children online, including advice and links to trusted resources.

Virtual private networks have many legitimate uses. The Government and Ofcom continue to monitor whether technologies can be used to seek to circumvent the protections of the Act for children.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what assessment she has made of the adequacy of online safety regulations for protecting people against harmful advice provided by AI chatbots.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

Services with AI chatbots regulated under the Online Safety Act have duties to protect all users from illegal content and children from age inappropiate content. This includes harmful advice if it is illegal content or meets the definition of harmful content to children under the Act.

The Government keeps all legislation under review and we will not hesitate to strengthen the law further if required.

Question to the Department for Business and Trade:

To ask the Secretary of State for Business and Trade, if he will make it his policy to adopt the recommendations of the Women and Equalities Committee's Sixth Report of Session 2024-25 entitled Equality at work: Paternity and shared parental leave, HC 502.

Answered by Kate Dearden - Parliamentary Under Secretary of State (Department for Business and Trade)

The Government thanks the committee for its careful consideration of Shared Parental Leave and Paternity Leave and has responded in full to the report. We recognise that more can be done to ensure working families are better supported. That is why on 1 July 2025 we launched the parental leave and pay review, which will consider all current and upcoming parental leave and pay entitlements. The recommendations and evidence outlined in the Women and Equality Committee’s report are important contributions to the review and we look forward to working with the committee as the thinking develops.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions he has had with the National Institute for Health and Care Excellence on securing long term access to cerliponase alfa.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Officials in the Department have had a number of discussions with colleagues in the National Institute for Health and Care Excellence (NICE) about the ongoing appraisal of cerliponase alfa (Brineura) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2). The Government understands the devastating impact of this condition on those affected, and how important the availability of effective new treatments is to patients and their families.

An agreement has now been reached between NHS England and the manufacturer of Brineura, BioMarin, that secures continued access for patients who have already started treatment with Brineura or who begin treatment before the end of this year.

NICE is, at present, unable to recommend Brineura for routine National Health Service funding for new patients in its draft guidance published in August. This decision comes after commercial negotiations between NHS England and BioMarin failed to secure a price for the treatment that properly reflects the limited evidence of its long-term effectiveness.

I recognise how disappointing this will be to all those affected, but I would like to underline that NICE has not yet concluded its appraisal. Stakeholders, including patient groups and the company, have had an opportunity to appeal the final draft guidance. If no appeal goes ahead, NICE expects to publish its final recommendations on cerliponase alfa in October.

Question to the Home Office:

To ask the Secretary of State for the Home Department, whether her Department has made an assessment of the potential impact of the appointment of Immigration Adjudicators on the asylum backlog.

Answered by Alex Norris - Minister of State (Home Office)

The Home Secretary confirmed in a statement to the House of Commons on 1 September that further information regarding Tribunal system reforms will be provided in due course. The statement can be accessed here: Borders and Asylum - Hansard - UK Parliament.

Question to the Ministry of Justice:

To ask the Secretary of State for Justice, what discussions he has had with Immigration and Asylum Tribunal Judges on the introduction of independent adjudicators to hear asylum appeals.

Answered by Sarah Sackman - Minister of State (Ministry of Justice)

It is standard practice not to comment on the specifics of discussions between ministers and the judiciary.

As would be expected, the Lord Chancellor has regular meetings with the Lady Chief Justice and other senior judges.

In line with constitutional conventions, discussions with the judiciary do not cover the merits of policy proposals and are limited to technical matters relating to the operation of the courts and the wider administration of justice.

Question to the Home Office:

To ask the Secretary of State for the Home Department, what funding she has allocated to tackle the asylum case backlog.

Answered by Alex Norris - Minister of State (Home Office)

The Home Office does not have a separately identifiable budget for tackling the asylum case backlog. All costs involved are scored against Home Office business-as-usual budgets that cover all asylum cases regardless of age.

You may find Home Office annual reports and accounts - GOV.UK useful, more specifically, the latest 2025 report and the accompanying core data table.

You can also see Migration transparency data - GOV.UK, table ASY_04 of Immigration and Protection data which contains information on the cost of asylum.

Question to the Department for Education:

To ask the Secretary of State for Education, what plans her Department has to ensure that funding through the School Rebuilding Programme is spent in line with (a) net zero standards and (b) sustainability goals.

Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)

The department commits to a wide range of actions in our Sustainability and Climate Change Strategy, including a requirement that all new school buildings we deliver are net-zero carbon in operation and are adapted to climate change. The strategy can be accessed at: https://www.gov.uk/government/publications/sustainability-and-climate-change-strategy.

All schools funded through the School Rebuilding Programme (SRP) have been designed to meet this standard, supporting the UK’s 25-year Environment Plan by requiring all projects to increase their level of greening in support of biodiversity net gain. The design principles of our output specification for SRP will ensure sites are more resilient to the impact of climate change and buildings delivered will achieve net zero carbon in operation.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure medicine shortages do not impact clinicians' ability to prescribe medicines that are best suited to the patient.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The resilience of UK supply chains is a key priority, and we are continually learning and seeking to improve the way we work to both manage and help prevent supply issues and avoid shortages. In August, the Government published a policy paper, ‘Managing a robust and resilient supply of medicines’, which outlines the steps the Department and NHS England are taking to enhance resilience in our supply chains. As part of that work, we continue to engage with industry, the Medicines and Healthcare products Regulatory Agency, and other colleagues across the supply chain as we progress work to co-design and deliver these actions.

While we cannot always prevent supply issues from occurring, we have a range of well-established processes and tools to manage them when they arise and mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols (SSPs), and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals including pharmacists, so they can advise and support their patients.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to decrease the level of the impact of medicine shortages on patients.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The resilience of UK supply chains is a key priority, and we are continually learning and seeking to improve the way we work to both manage and help prevent supply issues and avoid shortages. In August, the Government published a policy paper, ‘Managing a robust and resilient supply of medicines’, which outlines the steps the Department and NHS England are taking to enhance resilience in our supply chains. As part of that work, we continue to engage with industry, the Medicines and Healthcare products Regulatory Agency, and other colleagues across the supply chain as we progress work to co-design and deliver these actions.

While we cannot always prevent supply issues from occurring, we have a range of well-established processes and tools to manage them when they arise and mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols (SSPs), and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals including pharmacists, so they can advise and support their patients.

Question to the Ministry of Housing, Communities and Local Government:

To ask the Secretary of State for Housing, Communities and Local Government, what steps he is taking to ensure that management companies are maintaining newly built developments to agreed standards.

Answered by Matthew Pennycook - Minister of State (Housing, Communities and Local Government)

Estate management companies will usually agree standards for maintaining newly built developments with the developer at the time that the site is handed over to them. Where these standards are replicated in the agreement between the estate manager and the homeowner, failure to deliver services to this standard may be a breach of contract . In such instances, homeowners are able to make an application to the County Court to seek resolution.

In some instances, standards may be set through planning conditions and a failure to meet them may also be a breach of planning control. Local planning authorities have a wide range of enforcement powers, with strong penalties for non-compliance, which they can use where development is not maintained in accordance with the planning permission granted. It is for authorities to decide how and when they use their powers depending on the circumstances of each case.

The government remain committed to protecting residential freeholders on private and mixed-tenure housing estates from unfair charges. This year we will consult on implementing the Leasehold and Freehold Reform Act’s new consumer protection provisions for the up to 1.75m homes that are subject to these charges, and bring these measures into force as quickly as possible thereafter. These include ensuring that homeowners who pay an estate management charge have better access to information they need to understand what they are paying for, the right to challenge the reasonableness at the First-tier Tribunal (in England), and to go to the tribunal to appoint a substitute manager.

The government is determined to end the injustice of ‘fleecehold’ entirely and we will consult this year on legislative and policy options to reduce the prevalence of private estate management arrangements, which are the root cause of the problems experienced by many residential freeholders.

Question to the Ministry of Housing, Communities and Local Government:

To ask the Secretary of State for Housing, Communities and Local Government, what steps he is taking to assist local planning authorities in holding management companies to account for the maintenance of (a) roads and (b) public spaces under their remit.

Answered by Matthew Pennycook - Minister of State (Housing, Communities and Local Government)

Estate management companies will usually agree standards for maintaining newly built developments with the developer at the time that the site is handed over to them. Where these standards are replicated in the agreement between the estate manager and the homeowner, failure to deliver services to this standard may be a breach of contract . In such instances, homeowners are able to make an application to the County Court to seek resolution.

In some instances, standards may be set through planning conditions and a failure to meet them may also be a breach of planning control. Local planning authorities have a wide range of enforcement powers, with strong penalties for non-compliance, which they can use where development is not maintained in accordance with the planning permission granted. It is for authorities to decide how and when they use their powers depending on the circumstances of each case.

The government remain committed to protecting residential freeholders on private and mixed-tenure housing estates from unfair charges. This year we will consult on implementing the Leasehold and Freehold Reform Act’s new consumer protection provisions for the up to 1.75m homes that are subject to these charges, and bring these measures into force as quickly as possible thereafter. These include ensuring that homeowners who pay an estate management charge have better access to information they need to understand what they are paying for, the right to challenge the reasonableness at the First-tier Tribunal (in England), and to go to the tribunal to appoint a substitute manager.

The government is determined to end the injustice of ‘fleecehold’ entirely and we will consult this year on legislative and policy options to reduce the prevalence of private estate management arrangements, which are the root cause of the problems experienced by many residential freeholders.

Question to the Ministry of Housing, Communities and Local Government:

To ask the Secretary of State for Housing, Communities and Local Government, what steps he is taking to improve transparency in the purchasing property process.

Answered by Matthew Pennycook - Minister of State (Housing, Communities and Local Government)

On 6 October 2025, the government published a consultation on proposals to improve to the home buying and selling process. It can be found on gov.uk here.

The consultation includes proposals to require sellers and estate agents to provide upfront property information. This might include information relating to leasehold terms, property condition, and purchasing chains.

Under the Digital Markets, Competition and Consumers Act 2024, property listings must already not omit information that the average consumer needs to make an informed transactional decision.

Question to the Department for Digital, Culture, Media & Sport:

To ask the Secretary of State for Culture, Media and Sport, whether she has had discussions with the BBC Board on the UK's participation in the Eurovision Song Contest in the context of Israel's participation.

Answered by Ian Murray - Minister of State (Department for Science, Innovation and Technology)

The BBC is operationally and editorially independent from the Government. Therefore, the Government cannot intervene in the BBC’s day-to-day operations including on editorial matters.

Decisions on who to include in international events and competitions are for the organisers to take, within the framework of their own rules and regulations. It is for the EBU, in consultation with its members, to decide which countries are allowed to participate in Eurovision.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, If he will make an assessment of the adequacy of his Department's processes for (a) forecasting, (b) alerting and (c) responding to medicine shortages.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Medicine supply chains are complex, global and highly regulated and there are a number of reasons why supply can be disrupted – many of which are not specific to the United Kingdom and are outside of government control. This includes manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues.

The resilience of UK supply chains is a key priority, and we are continually learning and seeking to improve the way we work to both manage and help prevent supply issues and avoid shortages. In August, the government published a policy paper, ‘Managing a robust and resilient supply of medicines’, which provides transparency of the supply chains we rely on, the actions we take to protect patients from medicines shortages when they occur, and the steps the Department and NHS England are taking to enhance resilience in our supply chains. As part of that work, we continue to engage with industry, the Medicines and Healthcare products Regulatory Agency, and other colleagues across the supply chain as we progress work to co-design and deliver these actions.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent discussions he has had with NHS England on Innovative Medicines funding for givinostat.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Department officials have regular discussions with NHS England on a number of topics, including funding for innovative medicines.

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS independently, based on an assessment of their costs and benefits. The NHS in England is legally required to fund medicines recommended by NICE, normally within three months of the publication of final guidance.

NICE is currently evaluating givinostat for the treatment of Duchenne muscular dystrophy and, following a call for evidence, its Appraisal Committee will meet to consider its recommendations on 23 October 2025. NICE currently expects to publish final guidance in January 2026.

If recommended by NICE in draft guidance, my Rt Hon. Friend, the Secretary of State for Health and Social Care, has been clear that NHS England should aim to work with the pharmaceutical company, Italfarmaco, to provide early interim funding for givinostat through the Innovative Medicines Fund, which has made available £340 million of ringfenced funding for the NHS to fund early access to medicines. This could potentially speed up access to givinostat by up to five months.

To avoid the possibility of creating a way to circumvent the appraisal process, NHS England is unable to fund givinostat prior to the publication of draft NICE guidance that recommends the treatment.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the fortnightly notification provided to medicine suppliers regarding medicine shortages.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England’s medicines frameworks contain a contractual ask that requires all suppliers to update NHS England on their ability to supply their products to National Health Service hospitals.

This information is requested fortnightly and the responses are the basis by which NHS England’s medicines supply chain team assess current or potential upcoming medicines shortages.

This is a process designed to ensure the continuity of medicines supply for NHS hospitals and the information is not shared openly, but rather is only shared with specific relevant suppliers, who may be able to assist with the proposed mitigation plan.

A compilation of the mitigations is shared with all NHS hospitals and regional pharmacy procurement leads in order to support the implementation of the agreed actions locally.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of NHS tariff thresholds on pharmacies' ability to source medicines.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Evaluations by the National Institute for Health and Care Excellence (NICE) ensure that spend on new medicines represents a clinically and cost-effective use of National Health Service resources.

NICE thresholds should not have any impact on pharmacies’ ability to source medicines. Community pharmacies source the drugs they need to dispense against NHS prescriptions and will be reimbursed according to the prices and arrangements set out in the Drug Tariff. The United Kingdom has well established ways of managing the cost of medicines, ensuring pharmacies are appropriately reimbursed and clear processes in place to protect against risks to supply.

Question to the Department for Digital, Culture, Media & Sport:

To ask the Secretary of State for Culture, Media and Sport, if she will hold discussions with Ofcom on the effectiveness of the regulatory principles used to determine if an investigation should be carried out into comments made by media outlets.

Answered by Ian Murray - Minister of State (Department for Science, Innovation and Technology)

Ofcom, by law, carries out its investigations independently of the Government. Ofcom is accountable to Parliament, and the standards and objectives which underpin Ofcom’s rules and procedures are set out in legislation. Decisions over whether or not to investigate particular media outlets, and how they do that, are rightly a matter for Ofcom.

Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, whether she will make an assessment of the effectiveness of the enforcement of the Malicious Communications Act 1988.

Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)

The Online Safety Act introduced a number of communication offences, which were commenced in January 2024, including the false and threatening communications offences. The new communications offences have replaced the equivalent offences in the Malicious Communications Act 1988. In the January to December 2024 period, there were 14 convictions under the false communications offence and 294 under the threatening communications offence.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of IVF age limits on women who delay starting families for (a) educational, (b) career and (c) financial reasons.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Government recognises that fertility treatment across the National Health Service in England is subject to variation in access. Work continues between the Department and NHS England to better understand the offer around NHS-funded fertility services. This work will take time to develop, and the Department is keen to ensure there will be stakeholder engagement during this process, beginning in the new year.

Funding decisions for health services in England are made by integrated care boards (ICBs) and are based on the clinical needs of their population. We expect ICBs to commission fertility services in line with National Institute for Health and Care Excellence (NICE) guidelines, ensuring equal access to fertility treatment across England.

NICE develops its guidelines independent of the Government, based on the best available clinical evidence. The age limits recommended by NICE are informed by the chance of a live birth following in vitro fertilisation treatment falling with rising female age.

NICE is currently reviewing the fertility guidelines and will consider whether the current recommendations for access to NHS-funded treatment are still appropriate. A consultation on revised guidelines was published on 10 September.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that Integrated Care Boards implement National Institute for Health and Care Excellence guidance on access to NHS-funded IVF treatment.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Government recognises that fertility treatment across the National Health Service in England is subject to variation in access. Work continues between the Department and NHS England to better understand the offer around NHS-funded fertility services. This work will take time to develop, and the Department is keen to ensure there will be stakeholder engagement during this process, beginning in the new year.

Funding decisions for health services in England are made by integrated care boards (ICBs) and are based on the clinical needs of their population. We expect ICBs to commission fertility services in line with National Institute for Health and Care Excellence (NICE) guidelines, ensuring equal access to fertility treatment across England.

NICE develops its guidelines independent of the Government, based on the best available clinical evidence. The age limits recommended by NICE are informed by the chance of a live birth following in vitro fertilisation treatment falling with rising female age.

NICE is currently reviewing the fertility guidelines and will consider whether the current recommendations for access to NHS-funded treatment are still appropriate. A consultation on revised guidelines was published on 10 September.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of national funding allocations to Integrated Care Boards to support the delivery of levels of IVF treatment recommended by NICE.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

No assessment has been made. Funding decisions for health services in England are made by integrated care boards (ICBs) and are based on the clinical needs of their population. We expect ICBs to commission fertility services in line with National Institute for Health and Care Excellence guidelines, ensuring equal access to fertility treatment across England.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support NHS patient transport for (a) elderly people and (b) other patients.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

Non-Emergency Patient Transport Services (NEPTS) are designed to provide transport for patients who have particular clinical or mobility needs that necessitate such support, which may include elderly or vulnerable patients. The eligibility criteria for NEPTS have been set nationally by NHS England, and the details are available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2022/05/B1244-nepts-eligibility-criteria.pdf

The Healthcare Travel Cost Scheme (HTCS) is available for eligible patients and provides financial support to facilitate journeys to and from National Health Service funded secondary care. Details on the eligibility for HTCS is available at the following link:

https://www.nhs.uk/nhs-services/help-with-health-costs/healthcare-travel-costs-scheme-htcs/.

Local integrated care boards (ICBs) hold responsibility for the implementation of patient transport services at a local level, including monitoring and improving against performance targets. ICBs are best placed to work and consult with their local stakeholders, health and care organisations, and local authorities to decide how to best meet and deliver for the needs of their local population.

NHS England is funding and co-ordinating a range of Patient Transport Pathfinder projects to explore more effective approaches to supporting patients with their NHS travel needs.

Question to the Home Office:

To ask the Secretary of State for the Home Department, what steps she is taking to ensure that automated systems used by public bodies do not misclassify Irish citizens as requiring EU settled status documentation.

Answered by Alex Norris - Minister of State (Home Office)

The automated systems used by public bodies are the responsibility of the relevant organisation. Where a public body carries out automated checks with the Home Office, such checks will generally confirm whether the person holds a valid immigration status. The Home Office does not provide information or advice on what immigration status or documentation a person is required to hold as part of those checks. Irish citizens are treated as settled in the UK and are not required to hold an immigration status.

Insect decline and pesticide reduction

Recognition of Steve McBain’s contribution to the London Road underpass campaign

Government proposals for mandatory digital ID

Transparency and accountability in social media account closures

Conduct of the hon. Member for Runcorn and Helsby

Water bills

National Cancer Plan

Warm Homes Plan

Contribution of legal immigrants

Medical Defence Union 140th anniversary

Menopause Awareness Month

Future of BBC Radio 4 Longwave

40th anniversary of Breast Cancer Awareness Month

35 years of Macmillan Cancer Support’s Coffee Morning

Global Lobular Breast Cancer Awareness Day 2025

Fruit and Vegetable Aid Scheme

Protect our hospices

Renewable energy and coal

Access to school and college transport for disabled young people

25th anniversary of the UN Women, Peace and Security agenda

Protection of the Climate Change Act

Government review into Volumetric Concrete Mobile plants

Equitable national prostate cancer screening

National inquiry into child sexual exploitation

Naloxone

Conduct of Prince Andrew

Safety of British nationals aboard the Global Sumud Flotilla

Dr Anjana Khatwa

Elon Musk at the Unite the Kingdom rally

Leasehold reform (No. 2)

Children of Ukraine

Pavement parking consultation response

Independence of Healthwatch England

Dame Annette Brooke

Mental health care in Gaza

National Federation of Young Farmers’ Clubs (NFYFC) grant

Final delivery plan on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Intergenerational volunteering and sustainability initiatives

Unpaid Care Dashboard

Reinstatement of the Winter Fuel Payment

Shrill carder bee

Universities and international students

Sentencing Guidelines and pre-sentence reports

Drug-resistant superbugs

Maternity care in the UK

Pesticides in public spaces